Evidence map›Paper›PMID 25730665›Full record

ReviewJAMA neurology2015

Novel methods and technologies for 21st-century clinical trials: a review.

E Ray Dorsey, Charles Venuto, Vinayak Venkataraman, Denzil A Harris, Karl Kieburtz

Abstract readReview
In one paragraph

Review in JAMA neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Sample enrichment for clinical trials to show delay of onset in huntington disease.Movement disorders : official journal of the Movement Disorder Society · 2019
    Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Narrative review of telemedicine applications in decentralized research.Journal of clinical and translational science · 2024
    Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

E Ray DorseyDepartment of Neurology, University of Rochester Medical Center, Rochester, New York2Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York.
Charles VenutoDepartment of Neurology, University of Rochester Medical Center, Rochester, New York2Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York.
Vinayak Venkataramancurrently a medical student at Duke University School of Medicine, Durham, North Carolina.
Denzil A HarrisCenter for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York.
Karl KieburtzDepartment of Neurology, University of Rochester Medical Center, Rochester, New York2Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York4Clinical and Translational Sciences Institute, University of Roche.
University of Rochester Medical Center · USDuke University · US

Funding

The University of Rochester's Clinical and Translational Science InstituteUL1TR000042 · NCATS · UNIVERSITY OF ROCHESTER · PI BENNETT, NANCY M, KIEBURTZ, KARL D. · 2012 to 2015
$14.4M
EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASET32NS007338 · NINDS · UNIVERSITY OF ROCHESTER · PI ROBERT G. HOLLOWAY, Michael P McDermott · 1990 to 2026
$6.4M
Developing, evaluating, and disseminating new methods and technologies to advance Parkinson disease researchP20NS092529 · NINDS · UNIVERSITY OF ROCHESTER · PI DORSEY, EARL RAY · 2015 to 2016
$767k
NCATS NIH HHS UL1 TR000042NCATS NIH HHS UL1TR000042NINDS NIH HHS P20 NS092529NINDS NIH HHS T32 NS007338
6 · The paper itself

Abstract

importanceNew technologies are rapidly reshaping health care. However, their effect on drug development to date generally has been limited.

objectivesTo evaluate disease modeling and simulation, alternative study design, novel objective measures, virtual research visits, and enhanced participant engagement and to examine their potential effects as methods and tools on clinical trials. EVIDENCE REVIEW: We conducted a systematic search of relevant terms on PubMed (disease modeling and clinical trials; adaptive design, clinical trials, and neurology; Internet, clinical trials, and neurology; and telemedicine, clinical trials, and neurology), references of previous publications, and our files. The search encompassed articles published from January 1, 2000, through November 30, 2014, and produced 7976 articles, of which 22 were determined to be relevant and are included in this review.

findingsFew of these new methods and technologies have been applied to neurology clinical trials. Clinical outcomes, including cognitive and stroke outcomes, increasingly are captured remotely. Other therapeutic areas have successfully implemented many of these tools and technologies, including web-enabled clinical trials. CONCLUSIONS AND RELEVANCE: Increased use of new tools and approaches in future clinical trials can enhance the design, improve the assessment, and engage participants in the evaluation of novel therapies for neurologic disorders.

Indexed as

Clinical Trials as TopicHumansNervous System DiseasesNeurologyResearch Design

Identifiers

PMID25730665
PMCPMC4708881
OpenAlexW1969192849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.